Hisun Pharmaceutical: Innovative Drug HSK42360-Na Tablets Included in Breakthrough Therapy Designation Program

According to Haisco, recently, the innovative drug HSK42360-Na tablets independently developed by Haisco were officially included in the "Breakthrough Therapy Designation List" by the Center for Drug Evaluation of the National Medical Products Administration. After HSK42360-Na tablets are granted breakthrough therapy designation, it will greatly advance the research and development process of new drugs in this field, and the drug is expected to obtain priority review eligibility during the marketing application stage, accelerating its launch and bringing new hope for the treatment of glioma patients.